Cremedical
2 known investors
CREmedical develops brain sensing and neuromodulation technology, including its Tripolar Concentric Ring Electrode (TCRE) sensors, Tripolar EEG (tEEG) signal acquisition, and Transcranial Focal Electrical Stimulation (TFS). The platform cancels muscle and noise artifacts in real time and delivers Laplacian-based physiological signals for applications such as detecting biomarkers and modulating GABA and Glutamate.
Also known as CREmedical · CREmedical Corp
Investors · 2
Also in the syndicate · 1
Company profile
researched Aug 2026CREmedical is a developer of neurodiagnostic and neuromodulation technology built around the tripolar concentric ring electrode (TCRE), a sensor whose three closely spaced, concentric elements take bipolar differences of surface potentials to measure Laplacian potentials directly in hardware. The company positions this as an alternative to conventional electrode configurations and software filtering: the electrode geometry automatically cancels distant signals and noise such as muscle artifacts in real time, yields improved signal-to-noise ratio, enhanced spatial resolution and selectivity, and allows localization of the depth of electrical sources. The electrodes are described as suitable for EEG, ECG and EMG recording.
Two product lines sit on the sensor platform. On the sensing side, TCRE-based electroencephalography (tEEG) targets seizure detection, biomarker discovery, event-related potentials and brain-computer interfaces, with the claim that higher information content may reveal biomarkers not visible with standard EEG. On the stimulation side, transcranial focal electrical stimulation (TFS) delivers noninvasive focal stimulation through the concentric ring electrode's outer ring and center disc; the company reports animal-model results including stopped or reduced acute seizures, abolished status epilepticus, neuroprotection during status epilepticus, increased GABA and reduced glutamate. CREmedical describes an integrated tEEG+TFS platform for imaging brain function and modulating brain state. Catalogued products include the t-Lead TCRE-based sensor, the t-Interface 20 v2.0 (which configures electrode elements, routes and pre-amplifies signals), a concentric ring electrode for stimulation, and the Transcranial Focal Stimulator.
Founding story
CREmedical was founded in 2011 by Walter Besio, Ph.D., a professor of biomedical engineering at the University of Rhode Island who joined the URI faculty in 2008 after roughly a decade in the electronics and medical device industries. Besio is the inventor of the TCRE, tEEG and TFS technologies and has spent most of his research career on concentric ring electrodes through mathematical analysis, computer simulation and experiments in humans and animals. He is also a co-founder of URI's Interdisciplinary Neuroscience Program.
Business model
CREmedical develops and supplies hardware — TCRE-based sensors, signal-conditioning interfaces and a transcranial focal stimulator — with initial commercialization aimed at the research market and stated longer-term ambitions in diagnostic and therapeutic applications.
Traction
Approximately $1 million in NSF SBIR funding had been received as of May 2017, alongside seed investment from the URI Research Foundation and Slater Technology Fund. Founder Walter Besio had also brought several million dollars in research grants to URI from NSF, NIH, RI STAC and foundations. Products are catalogued by distributor Brain Vision, and TFS results have been reported in multiple animal models.
Latest developments
In May 2017 the Slater Technology Fund and the URI Research Foundation announced expanded seed funding for CREmedical to advance technology development and support a launch in the research market.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
CREmedical describes itself, and is described by its distributor, as the pioneer of tripolar concentric ring electrodes, positioning its hardware-based artifact cancellation against standard electrode configurations and software-filtered EEG.
Artifact and noise suppression is achieved by electrode geometry at the point of acquisition, so the output is presented as direct physiological measurement (Laplacian potentials) rather than software-transformed data; the same electrode design also enables focal, noninvasive stimulation and depth localization of electrical sources.
Technology
The core technology is the tripolar concentric ring electrode, which performs the Laplacian operation in the electrode itself by taking bipolar differences among three closely spaced concentric elements, thereby cancelling distant signals and noise at acquisition rather than in post-processing software. Derived offerings are tEEG (TCRE-based electroencephalography) for high-fidelity, high-spatial-resolution brain sensing and TFS (transcranial focal electrical stimulation) delivered noninvasively via the electrode's outer ring and center disc, plus the t-Interface signal routing and pre-amplification unit.
Go-to-market
Direct presentation of the platform through the company's own site, complemented by distribution and scientific-consultant support through Brain Vision, which lists the t-Lead, t-Interface 20 v2.0, concentric ring stimulation electrode and Transcranial Focal Stimulator in its vendor catalogue.
Neuroscience and clinical researchers working on seizure detection, biomarker discovery, event-related potentials, brain-computer interfaces and neuromodulation; the initial commercial focus stated by investors was the research market, with diagnostic and therapeutic uses as later targets.
Geography
Rhode Island, United States, with roots at the University of Rhode Island; products are listed by a distributor serving the United States, Canada and international customers.
History
The company was founded in 2011 out of research at the University of Rhode Island. By 2017 it had received approximately $1 million in Small Business Innovation Research funding from the National Science Foundation, and in May 2017 the URI Research Foundation and the Slater Technology Fund announced expanded seed funding to support technology development and to help recruit a business partner. Its research-market products are also listed through distributor Brain Vision.
Risks & controversies
As of the 2017 seed announcement, the company was still seeking a business partner with relevant commercial background and further follow-on financing, and its stimulation efficacy evidence was drawn from animal models.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsThe Slater Technology Fund committed $250,000 alongside the URI Research Foundation, which made an initial $30,000 investment followed by a $62,500 co-investment. Proceeds were designated for further technology development and to attract a business partner with relevant background and experience.
$342.5K source ↗
CREmedical's clinical collaborators were reported to be anchored by Robert Fisher, M.D., Ph.D., professor of neurology at Stanford Medical School and director of the Epilepsy Center at Stanford Hospital.
The company was founded in 2011 by Walter Besio, Ph.D., professor of biomedical engineering at the University of Rhode Island.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Cremedicalcremedical.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cremedical do?
- CREmedical develops tripolar concentric ring electrode sensors for EEG recording and transcranial focal electrical stimulation.
- Who are Cremedical's investors?
- Cremedical's investors include Slater Technology Fund.